Finanças

Notícias Discussões Sinais técnicos Previsão Sazonais Opções Títulos

EBITDA de BridgeBio Pharma, Inc..

Dados anuais

2018

2019

2020

2021

2022

2023

2024

TTM

‪‪−600,00 M‬‬

‪‪−450,00 M‬‬

‪‪−300,00 M‬‬

‪‪−150,00 M‬‬

‪0,00‬

Período

Valor

Variação

Variação %

TTM

‪‪−571,29 M‬‬

‪0,00‬

‪0,00‬%

2024

‪‪−571,29 M‬‬

+‪‪21,66 M‬‬

+‪3,65‬%

2023

‪‪−592,95 M‬‬

‪‪−131,28 M‬‬

‪−28,44‬%

2022

‪‪−461,67 M‬‬

+‪‪109,12 M‬‬

+‪19,12‬%

2021

‪‪−570,79 M‬‬

‪‪−99,39 M‬‬

‪−21,09‬%

2020

‪‪−471,39 M‬‬

‪‪−205,15 M‬‬

‪−77,06‬%

2019

2018

Dados trimestrais

Q2 '18

Q3 '18

Q1 '19

Q2 '19

Q3 '19

Q4 '19

Q1 '20

Q2 '20

Q3 '20

Q4 '20

Q1 '21

Q2 '21

Q3 '21

Q4 '21

Q1 '22

Q2 '22

Q3 '22

Q4 '22

Q1 '23

Q2 '23

Q3 '23

Q4 '23

Q1 '24

Q2 '24

Q3 '24

Q4 '24

‪‪−240,00 M‬‬

‪‪−160,00 M‬‬

‪‪−80,00 M‬‬

‪0,00‬

‪‪80,00 M‬‬

Período

Valor

Variação

Variação %

Q4 '24

‪‪−219,97 M‬‬

‪‪−34,38 M‬‬

‪−18,52‬%

Q3 '24

‪‪−185,59 M‬‬

‪‪−14,52 M‬‬

‪−8,49‬%

Q2 '24

‪‪−171,07 M‬‬

‪‪−176,41 M‬‬

‪‪−3,30 K‬‬%

Q1 '24

‪‪5,34 M‬‬

+‪‪180,42 M‬‬

—

Q4 '23

‪‪−175,08 M‬‬

‪‪−19,30 M‬‬

‪−12,39‬%

Q3 '23

‪‪−155,78 M‬‬

‪‪−14,85 M‬‬

‪−10,54‬%

Q2 '23

‪‪−140,93 M‬‬

‪‪−19,77 M‬‬

‪−16,32‬%

Q1 '23

‪‪−121,16 M‬‬

‪‪−1,28 M‬‬

‪−1,07‬%

Q4 '22

Q3 '22

Q2 '22

Q1 '22

Q4 '21

Q3 '21

Q2 '21

Q1 '21

Q4 '20

Q3 '20

Q2 '20

Q1 '20

Q4 '19

Q3 '19

Q2 '19

Q1 '19

Q3 '18

Q2 '18